U.S. Personal Products Stock News

Sonic Automotive (SAH) has put up a mixed scorecard for FY 2025 so far, with Q3 revenue of US$4.0b, basic EPS of US$1.38 and net income of US$46.8m, alongside reported trailing 12 month revenue of US$15.2b and basic EPS of US$3.82. The company has seen quarterly revenue move from US$3.5b in Q3 2024 to US$4.0b in Q3 2025, while basic EPS has shifted from US$2.18 to US$1.38 over the same periods. This sets up a story where decent top line momentum meets thinner margins and leaves investors...

If you are wondering whether ServiceNow is starting to look attractively priced after a rough patch, you are not alone. This article will walk through what the current share price might mean for long term investors. The stock has recently shown a mixed return profile, with a 7.2% gain over the last 7 days, a 15.3% decline over 30 days, and year to date and 1 year returns of 26.9% and 45.4% declines respectively, while the 3 year return sits at 22.6% and the 5 year return at a 2.3%...

Insulet (PODD) just put up third quarter FY 2025 numbers with revenue of US$706.3 million and basic EPS of US$1.24, alongside net income of US$87.6 million, setting the tone for how the rest of the year is shaping up. The company has seen revenue move from US$488.5 million in Q2 2024 to US$649.1 million in Q2 2025 and US$706.3 million in Q3 2025, while basic EPS shifted from US$2.69 to US$0.32 and then US$1.24 over the same quarters. This gives investors a clear view of how the top line and...

Caesars Entertainment (CZR) closed out FY 2025 with fourth quarter revenue of US$2.9 billion, a basic EPS loss of US$1.23 and a net income loss of US$250 million, compared with revenue of US$2.8 billion, basic EPS of US$0.05 and net income of US$11 million in the same quarter a year earlier. Over the past year, the company has seen quarterly revenue range from US$2.8 billion to US$2.9 billion, while basic EPS moved from a US$0.27 loss in Q3 2025 to a US$1.23 loss in Q4 2025. Trailing twelve...

Element Solutions (ESI) just wrapped up FY 2025 with fourth quarter revenue of US$676.2 million and basic EPS of US$0.03, alongside trailing twelve month revenue of US$2.6 billion and EPS of US$0.79 that sit against a net profit margin of 7.5%. Over recent quarters the company has seen revenue move from US$593.7 million and EPS of US$0.40 in Q1 2025 to US$676.2 million and EPS of US$0.03 in Q4 2025, while the last 12 months also include a US$59.0 million one off gain and a P/E of 42.9x that...

If you are wondering whether Vistra's current share price really reflects its value, you are not alone. That is exactly what this article will unpack. Vistra closed at US$170.57, with returns of 6.5% over the last 7 days, 2.4% over 30 days, 3.2% year to date, 1.3% over 1 year and a very large return over 3 and 5 years that is close to 7x. Recent headlines around Vistra have focused on its position in the US utilities sector, including market interest in how it is managing its generation...

JBG SMITH Properties (JBGS) has capped FY 2025 with fourth quarter revenue of US$127.7 million, a basic EPS loss of US$0.75, and funds from operations of US$13.9 million in losses, setting a cautious tone around earnings quality. The company has seen quarterly revenue move from US$130.4 million in Q4 2024 to US$127.7 million in Q4 2025. Trailing twelve month revenue sits at US$498.6 million and EPS over the same period is a loss of US$2.06, which keeps the focus squarely on how efficiently...

Humacyte (HUMA) is back in focus after presenting long term Symvess data from the V005 trial at the VESS 2026 Winter Meeting, highlighting durability, low infection rates, and sustained limb salvage in complex trauma cases. See our latest analysis for Humacyte. Humacyte’s recent Symvess data arrives after a mixed share price run, with a 7 day share price return of 6.93% but a 1 year total shareholder return of a 72.09% loss, which points to short term momentum rebuilding against a weak longer...

USANA Health Sciences (USNA) closed FY 2025 with Q4 revenue of US$226.2 million and a basic EPS loss of US$0.10, as net income excluding extra items came in at a loss of US$1.8 million. Over the last six reported quarters, revenue has moved between US$200.2 million and US$249.5 million, while quarterly basic EPS has ranged from a profit of US$0.56 to a loss of US$0.36, and trailing twelve month EPS stood at US$0.58 on revenue of US$925.3 million in Q4 2025. For investors, the key story this...

MKS (MKSI) has wrapped up FY 2025 with Q4 revenue of US$1.0b and basic EPS of US$1.60, alongside trailing twelve month revenue of US$3.9b and EPS of US$4.38 that sit against a 55.3% earnings lift over the past year. The company has seen quarterly revenue move from US$934m in Q4 2024 to US$1.0b in Q4 2025, while basic EPS shifted from US$1.35 to US$1.60 over the same period. Analysts are forecasting 27.9% annual earnings growth and higher net profit margins, keeping investor attention firmly...

Mach Natural Resources (NYSE:MNR) is working through integration challenges tied to newly acquired oil assets in the Central Basin Platform. At the same time, the company has announced an increase in its quarterly cash distribution to unitholders. The combination of operational complexity and higher cash returns has drawn fresh attention from investors and analysts. Mach Natural Resources comes into this news with a recent unit price of $13.31 and a mixed return profile. The units are up...

In recent updates, Spyre Therapeutics outlined its 2026 plans, highlighting accelerated timelines for six proof-of-concept readouts, including the SKYLINE ulcerative colitis trial completing enrollment earlier than initially expected, and confirmed that the SKYWAY basket trial remains on schedule for later-stage data. The company also recently appointed Kate Tansey Chevlen as Chief Commercial Officer, signaling a growing emphasis on commercial readiness alongside its advancing inflammatory...

If you are wondering whether AngloGold Ashanti at around US$106 per share still offers value after a strong run, this article will walk through what the current price might imply. The stock has had a mixed short term patch, with a 2.2% decline over the last 7 days, a 7.2% gain over 30 days, and returns of 24.0% year to date and 246.5% over the past year, while the 3 year return is very large and the 5 year return is more than 4x. Recent coverage has focused on AngloGold Ashanti's move to the...

NewAmsterdam Pharma has begun late stage RUBENS Phase 3 trials of obicetrapib in patients with Type 2 diabetes and metabolic syndrome. The company also plans to launch a new trial of obicetrapib in early Alzheimer's disease. These programs expand obicetrapib's potential use into major cardiometabolic and neurological conditions. For investors watching NasdaqGM:NAMS, these trial moves come as the stock trades at $35.24 and has returned 75.8% over the past year and 237.2% over the past five...

Why TAL Education Group Is On Investors’ Radar Today TAL Education Group (NYSE:TAL) has drawn fresh attention after recent share price moves, with the stock down 3.2% over the past day and showing weaker returns across the week, month, past 3 months, and year. See our latest analysis for TAL Education Group. The recent 1 day share price decline of 3.2% to US$10.89 extends a weaker trend, with a 7 day share price return of 11.25% and a 1 year total shareholder return decline of 24.9%,...

Planet Fitness (NYSE:PLNT) has signed a new franchise agreement with Impulso Gym to expand its footprint in Mexico. The company is growing its presence in markets where fitness club penetration is relatively low. Planet Fitness has also appointed Stephen Beard, an experienced executive in education and organizational transformation, to its board of directors. For investors, this move into Mexico highlights how Planet Fitness is focusing on international opportunities where gym membership...

Wondering whether Insmed's current share price lines up with its underlying value, or if expectations have simply run ahead of the story. The stock last closed at US$150.52, with returns of 1.3% over 7 days, a 6.8% decline over 30 days, a 15.0% decline year to date, and 85.0% over the past year, which naturally raises questions about how much optimism is already in the price. Recent news coverage has focused heavily on Insmed's progress and prospects in the pharmaceuticals and biotech space...

If you are trying to figure out whether Bitgo Holdings at around US$10.87 is a bargain or a value trap, starting with a clear view of what the current price reflects can help you frame the opportunity and the risks. The stock has seen a 1.4% decline over the last 7 days and a 41.2% decline year to date, which can change how the market views its growth potential and risk profile. Recent coverage around Bitgo Holdings has focused on its role in digital asset custody and broader crypto market...

Investors may be wondering whether Devon Energy at around US$44.04 is offering good value right now, or if most of the opportunity is already priced in. The stock has returned 1.3% over the last 7 days, 21.7% over the last 30 days, 16.3% year to date, 29.8% over 1 year, and 164.3% over 5 years, while the 3 year return sits at a 7.4% decline. This gives a mixed picture of how the market has treated the shares over time. Recent coverage has focused on Devon Energy's position in the US energy...

In February 2026, Black Hills Corporation reported past fourth-quarter 2025 results showing sales of US$635.5 million and net income of US$104.9 million, with diluted earnings per share from continuing operations of US$1.39. For the full year 2025, Black Hills grew sales to US$2.31 billion and net income to US$291.6 million, with diluted continuing EPS of US$3.98, highlighting consistent year-on-year earnings expansion. We’ll now consider how this earnings growth, particularly the full-year...

Why Canaan’s latest numbers matter for shareholders Canaan (NasdaqGM:CAN) just released fourth quarter and full year 2025 results, fresh earnings guidance for the first quarter of 2026, and January Bitcoin production data, giving investors several new reference points to assess the stock. For the fourth quarter ended December 31, 2025, Canaan reported revenue of US$196.27 million, compared with US$88.77 million a year earlier. The company recorded a net loss of US$85.04 million for the...

Charles River Laboratories International (NYSE:CRL) has appointed Glenn G. Coleman as Chief Financial Officer. The company has also named Kerry Dailey as Chief Legal Officer, expanding its senior leadership bench. These leadership changes are aimed at reinforcing financial oversight, legal governance, and corporate compliance. Charles River Laboratories operates as a key partner for pharmaceutical and biotech companies, supporting drug discovery, preclinical research, and related services...

The Brink’s Company has appointed Adrian Button as executive vice president and president of Brink’s North America, effective February 16, 2026, adding him to the executive leadership team reporting to CEO Mark Eubanks. With more than 30 years of global operational leadership at GE, NCR, and Carrier overseeing multibillion-dollar businesses and large-scale supply chains, Button’s background directly aligns with Brink’s focus on operational efficiency and service quality in North...

If you are wondering whether Texas Capital Bancshares at around US$104 is offering good value or asking too much, you are in the right place. The stock closed at US$104.37 recently, with returns of 1.3% over the last week, 6.5% over the last month, 13.8% year to date, 27.0% over one year and 60.3% over three years, as well as 30.9% over five years. These moves may have shifted how the market views its potential and risks. Recent coverage around Texas Capital Bancshares has focused on its...